Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 3;18(1):159.
doi: 10.1186/s12879-018-3061-5.

Prevalence of carbapenem-resistant Acinetobacter baumannii from 2005 to 2016 in Switzerland

A Ramette  1 , A Kronenberg  2 ; the Swiss Centre for Antibiotic Resistance (ANRESIS)
Collaborators, Affiliations

Prevalence of carbapenem-resistant Acinetobacter baumannii from 2005 to 2016 in Switzerland

A Ramette et al. BMC Infect Dis. .

Abstract

Background: We describe the prevalence of invasive carbapenem-resistant Acinetobacter spp. isolated from 2005 to 2016 in different regions of Switzerland.

Methods: Using the Swiss Antibiotic Resistance Centre (anresis) database that includes data from 70% of all hospitalized patients and one third of all ambulatory practitioners in Switzerland, we analysed the number of carbapenem-susceptible and resistant Acinetobacter spp. isolated from blood or cerebrospinal fluid, and further described their temporal and regional fluctuations.

Results: From 2005 to 2016, 58 cases of resistant or intermediate strains to carbapenem were observed among 632 cases of invasive Acinetobacter. Multivariable analyses indicated that the number of carbapenem-resistant isolates (mean 4.8 ± sd 2.12) and carbapenem resistance rates per region per annum (8.4% ± 13.9%) were low and stable over the studied period. Large fluctuations were observed at the regional level, with e.g. the North East region displaying resistance rates twice as high as that found in other regions.

Conclusion: Despite a relatively stable number of carbapenem-resistant Acinetobacter isolates in Switzerland, our results suggest the existence of a diverse pool of A. baumannii species in hospital settings, and confirm the implication of carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii (ACB) complex in the vast majority of clinical infections and nosocomial outbreaks with notable regional fluctuations.

Keywords: Acinetobacter baumannii complex; Carbapenem resistance; Epidemiology; Regional trends; Surveillance; Temporal trends.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Analysis and publication of the data presented in the study were done in agreement with the steering committee of the Swiss Centre for Antibiotic Resistance (ANRESIS).

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
a Acinetobacter resistance rates (number of resistant isolates compared to total number of isolates) per region from 2005 to 2016 in Switzerland. Standard deviation bars represent annual fluctuations per region. b Map of the Swiss regions defined in this study. The original map template, which was made freely available by the Federal Statistical Office (https://www.bfs.admin.ch/bfs/en/home/statistics/regional-statistics/maps.html), was modified by the authors. c Frequency of isolation of resistant Acinetobacter across Swiss regions from 2005 to 2016 (daily resolution). d Acinetobacter resistance rates per year and per region in Switzerland
See this image and copyright information in PMC

References

    1. Nemec A, Krizova L, Maixnerova M, van der Reijden TJ, Deschaght P, Passet V, et al. Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU) Res Microbiol. 2011;162(4):393–404. doi: 10.1016/j.resmic.2011.02.006. - DOI - PubMed
    1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–582. doi: 10.1128/CMR.00058-07. - DOI - PMC - PubMed
    1. Yakut N, Kepenekli EK, Karaaslan A, Atici S, Akkoc G, Demir SO, et al. Bacteremia due to Acinetobacter ursingii in infants: reports of two cases. Pan Afr Med J. 2016;23:193. doi: 10.11604/pamj.2016.23.193.8545. - DOI - PMC - PubMed
    1. Sieswerda E, Schade RP, Bosch T, de Vries J, Chamuleau MED, Haarman EG, et al. Emergence of carbapenemase-producing Acinetobacter ursingii in the Netherlands. Clin Microbiol Infect. 2017;23(10):779–781. doi: 10.1016/j.cmi.2017.04.024. - DOI - PubMed
    1. Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med. 2015;36(1):85–98. doi: 10.1055/s-0034-1398388. - DOI - PMC - PubMed

Publication types

MeSH terms